1.
CHEMISTRY

General Considerations
All solvents and reagents were commercially available and used without further purification unless otherwise stated.
NMR spectra were recorded with a Varian 400 MHz instrument at room temperature with tetramethylsilane (TMS)
as an internal standard. Mass spectra were performed on a Agilent Q-TOF HPLC-MS or VG (Micromass) 70-250-S Magnetic sector mass spectrometer employing the electrospray ionization (ESI) method or electron ionization (EI) method. High performance liquid chromatography (HPLC) was performed using a Shimadzu LC-2010A HT system equipped with a Bioscan B-FC-1000 radiation detector. All procedures including anhydrous solvents were performed with rigorously dried glassware under inert atmosphere. 0  10  20  30  40  50  60  70  80  90  100  110  120  130  140  150  160  170  180  190 f1 (ppm) Thioisocynate 4 (0.225 g, 1.01 mmol; assumed 100 % conversion) was dissolved in EtOH (2 ml, 0.5 M), and 1-(3-aminopropyl)imidazole (0.241 mL, 2.02 mmol) was added. The solution was heated to and held at reflux for 2 h.
Synthesis Procedures
The solvent was removed in vacuo and the product was recrystallized from EtOH and purified by silica gel chromatography (DCM, MeOH gradient) to give the product as a white powder; (0.13 g, 41 % yield for two steps); UV Detector Ch1-254nm Results 
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RADIOCHEMISTRY
General Radiochemistry Considerations
Reagents and solvents were commercially available and used without further purification, unless otherwise noted: sodium chloride, 0.9% USP and sterile water for Injection, USP were purchased from Hospira; Dehydrated Alcohol for Injection, USP was obtained from Akorn Inc.; Ascorbic Acid for Injection, USP was acquired from Bioniche Pharma; Ammonium Bicarbonate was obtained from Fisher Scientific. Shimalite-Nickel was purchased from Shimadzu; iodine was obtained from EMD; phosphorus pentoxide was acquired from Fluka; molecular sieves were purchased from Alltech; and HPLC columns were acquired from Phenomenex. Other synthesis components were obtained as follows: sterile filters were acquired from Millipore; C18-light Sep-Paks and Porapak Q were purchased from Waters Corporation; 10 cc sterile vials were obtained from Hollister-Stier. Sep-Paks were flushed with 10 mL of ethanol followed by 10 mL of sterile water prior to use. The desmethylprecursor 5 (1 mg) was dissolved in 0.1 mL of DMF. To this mixture 10 µL of sat. K 2 CO 3(aq.)
Synthesis of [ 11 C]PBD150
solution was added and the resulting mixture was mixed thoroughly. The mixture was dried over Na 2 SO 4 and the solution was transferred to the reactor (careful not include any of the hydrated Na 2 SO 4 ). The reaction solution was sparged with [ 11 C]MeOTf at a flow rate of 15 mL/min for 3-5 min. The reaction mixture was then purified via semipreparative HPLC (column: Phenomenex Luna C18, 150x10 mm, mobile phase: 10 mMolar Na 2 HPO 4 , 500 mg/L ascorbic acid in 20 % EtOH, pH 8.0, flow rate: 4 mL/min; see Figure S20 for a typical trace). The product peak was collected at ~8-9 min (collected for 30 seconds at peak of product elution, 2 mL collected) and diluted into 8 mL of saline for a final volume of 10 mL (~4 % v/v EtOH). The dose was passed through a 0.22-µm filter into a sterile S17 dose vial. The synthesis resulted in 66.1 mCi of product collected (7.3% yield from [ 11 C]MeOTf, non-decay corrected, specific activity = 5.7 Ci/µmol, n = 5). The final product was then submitted for quality control testing (see Section 3.3). 
Quality Control of [ 11 C]PBD150
Radiochemical purity of [ 11 C]PBD150 was assessed using Shimadzu LC-2010A HT system equipped with the UV and Rad detectors (column: Phenomenex Luna C18, 150x4.6 mm; mobile phase: 10 mM NH 4 OAc in 20% MeCN; flow rate: 2.0 mL/min; wavelength: 254 nm; room temperature; product peak: ~4.2 min; see Figure S21 for a typical trace). The pH of the dose solution was determined (pH = 7.0, n = 5) and radiochemical purity was assessed before use in animal imaging experiments (radiochemical purity ≥95%, n = 5). 
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Notes on Failed Radiosyntheses of [ 11 C]PBD150
The procedure for synthesizing [ 11 C]PBD150 outlined in Section 3.2 was followed except 1 mg of NaH was employed as the base. Following 11 C-methylation, the crude reaction mixture was analyzed by HPLC ( Figure S22 ). 
4.
SMALL ANIMAL PRE-CLINICAL PET IMAGING
General Considerations
All animal studies were performed in accordance with the standards set by the University Committee on Use and
Care of Animals (UCUCA) at the University of Michigan. Doses of [ 11 C]PBD150 were used within 5 -10 mins of recording specific activity at EOS.
Baseline Imaging Study in Mouse
The mouse imaging study was performed in a female CD-1 mouse (n = 1, weight = 21 g). The rat was anesthetized min frames -4 x 5 min frames -3 x 10 min frames). Image data were corrected for attenuation and scatter, and then reconstructed using the 3D maximum a priori (3D MAP) algorithm ( Figure S23 ). By using a summed image, regions of interest (ROI) were drawn over the whole brain on multiple planes, and the volumetric ROIs were then applied to the full dynamic data set to generate time-radioactivity curves which confirmed no brain uptake (data not shown). 
Baseline Imaging Study in Rat
Baseline rat imaging studies were performed with female Sprague-Dawley rats (n = 2, weight = 308g, 346g). Rats were anesthetized (isoflurane), and positioned in a Concorde MicroPET P4 scanner. Following a transmission scan, the animals were injected i.v. (tail vein) with [ 11 C]PBD150 (1.01 ± 0.09 mCi) as a bolus over 1 min, and the brain imaged for 60 min (5 x 2 min frames -4 x 5 min frames -3 x 10 min frames). Image data were corrected for attenuation and scatter, and then reconstructed using the 3D maximum a priori (3D MAP) algorithm ( Figure S24 ).
By using a summed image, regions of interest (ROI) were drawn over the whole brain on multiple planes, and the volumetric ROIs were then applied to the full dynamic data set to generate time-radioactivity curves ( Figure S27 ). 
Cyclosporin Blocking Study in Rat
The imaging experiment described in Section 4.3 was repeated using a female Sprague Dawley rat (n = 1, animal weight = 294 g) pre-treated with cyclosporin A (manufactured for Bedford Labs, Bedford, OH. Lot # 1856175, each ml contains cyclosporin USP 50 mg; polyoxyethyated castor oil 650 mg; and absolute alcohol 33.2% (v/v)) per the procedure reported by Blanckaert et al. 4 Each rat was injected i.v. with 50mg/kg (approx. 0.3 mL of stock was diluted to 1.0 mL with saline) over a 3 minute infusion, one hr. prior to administration of the [ 11 C]PBD150 tracer dose (0.94 mCi). The brain was then scanned for 60 min as described in Section 4.3. Data were corrected for attenuation and scatter, and reconstructed using the 3D MAP method ( Figure S25 ). Using a summed image, ROIs were drawn and time-radioactivity curves generated as described in Section 4.3 ( Figure S27 ). 
Co-administration of PBD150 Therapeutic Dose in Rat
The imaging experiment described in Section 4.3 was repeated using a female Sprague Dawley rat (n = 1, animal weight = 323 g). The radiotracer dose (1.07 mCi) was formulated with unlabelled PBD150 (12 mg corresponding to a dosage of 37 mg/kg) and administered i.v. via tail vein injection. The brain was then scanned for 60 min as described in Section 4.3. Data were corrected for attenuation and scatter, and reconstructed using the 3D MAP method ( Figure S26 ). Using a summed image, ROIs were drawn and time-radioactivity curves generated as described in Section 4.3 ( Figure S27 ). 
Time Radioactivity Curves
Using summed images, regions of interest (ROI) were drawn over the whole brain on multiple planes, and the volumetric ROIs were then applied to the full dynamic data set to generate time-radioactivity curves ( Figure S27 ). 
RAT MICROSOME STABILITY STUDY Materials
Pooled rat microsomes were stored at -80 C prior to use.
Study design
The microsome incubation system was prepared according to the Table S1 .
1. Make a master-mix containing microsome, phosphate buffer and NADPH solution as follows:
1) Dilute 10μL of microsome (20 mg/mL) with 330 μL 0.1M Phosphate buffer (3.3 mM MgCl 2 );
2) Dissolve about 2 mg of NADPH in 120 μL of 0.1M phosphate buffer (3.3 mM MgCl 2 );
3) Addition of 40 μL of 10uM test compound to microsome; 4) Pre-warm the master solution in the 37℃ for 3 min.
2. Add 20μL NADPH to the above master solution to initiate the reaction according to Table S1 . The final concentration of test compounds in the reaction system is 1μM. 
Data Analysis
The natural log peak area ratio (compound peak area/ internal standard peak area) was plotted against time and the gradient of the line determined.
LC-MS/MS Conditions
Chromatographic Conditions: 
Metabolic Stability
The metabolic stability and biological t 1/2 of test PBD150 in liver microsome with NADPH is listed in Table S2 , and plotted in the Figure S28 . 
